Vitamin K Antagonist - Drug

DRUG3 trials

Sponsors

Onze Lieve Vrouw Hospital, Groupe Maladies hémorragiques de Bretagne, Assistance Publique - Hôpitaux de Paris

Conditions

Anticoagulant-induced BleedingAntiphospholipid SyndromeAtrial FibrillationHemophilia AHemophilia BThrombosisThrombotic Antiphospholipid Syndrome

Phase 3

Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome

Not yet recruitingNCT07875153

Assistance Publique - Hôpitaux de ParisAntiphospholipid Syndrome, Thrombosis, Thrombotic Antiphospholipid Syndrome

Start: 2026-12-01End: 2031-01-01Target: 234Updated: 2026-10-15

Phase 4

Oral Anticoagulation in Hemodialysis

CompletedNCT03799822

Onze Lieve Vrouw HospitalAtrial Fibrillation

Start: 2017-05-01End: 2020-10-01Updated: 2020-11-03

Unknown Phase

Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia

CompletedNCT05804734

Groupe Maladies hémorragiques de BretagneAnticoagulant-induced Bleeding, Hemophilia A, Hemophilia B

Start: 2021-06-01End: 2021-12-31Updated: 2023-04-07

Related Papers

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial

Journal of the American Society of Nephrology2021-03-22170 citations